Word

Status

Registered

Status Code

700

Status Date

Tuesday, October 8, 2019

Serial Number

79239066

Registration Number

5876245

Registration Date

Tuesday, October 8, 2019

Mark Type

2000

Filing Date

Tuesday, May 22, 2018

Published for Opposition

Tuesday, July 23, 2019

Trademark Owner History

Sichuan Jishengtang Pharmaceutical Co.,Ltd. - Original Registrant

Classifications

5 Chinese medicine nostrum in the nature of traditional Chinese medicines for treating influenza, depression, cough, diabetes, hypertension, respiratory diseases, cardiovascular disease, intestinal disorders, gastrointestinal diseases, hyperlipidemia, and hypercholesterolemia; medicines for human purposes, namely, medicines for treating hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, vision loss and blindness in the elderly; chemico-pharmaceutical preparations for treating hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, vision loss and blindness in the elderly; pharmaceutical preparations for treating hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, vision loss and blindness in the elderly; active ingredient, namely, dietary fiber for use in the manufacture of pharmaceuticals for treating hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, vision loss and blindness in the elderly; biochemical drugs for treating cancer and eye diseases; chemical preparations for pharmaceutical purposes, namely, chemical preparations for treating hepatitis, dizziness, cardiovascular diseases, cerebrovascular diseases, depression, schizophrenia, insomnia, cholecystitis, gallstones, stomach diseases, digestive diseases, restlessness, laryngitis, pharyngitis, tonsillitis, tracheitis, pneumonia, influenza, cough, diabetes, nephropathy, eye diseases, vision loss and blindness in the elderly; nutritive substances for microorganisms for medical purposes

Color is not claimed as a feature of the mark.
THE NON-LATIN CHARACTER THAT TRANSLITERATES TO "JI"
The mark consists of three Chinese characters.
The non-Latin characters in the mark transliterate to "JI SHENG TANG" and this means "AID," "GROW" and "HALL" respectively in English.

Trademark Events

Jun 5, 2021

New Representative At Ib Received

Mar 13, 2020

Final Decision Transaction Processed By Ib

Feb 4, 2020

Generic Madrid Transaction Sent To Ib

Feb 4, 2020

Generic Madrid Transaction Created

Jan 8, 2020

Final Disposition Notice Created, To Be Sent To Ib

Oct 8, 2019

Registered-Principal Register

Aug 2, 2019

Notification Processed By Ib

Jul 23, 2019

Official Gazette Publication Confirmation E-Mailed

Jul 23, 2019

Published For Opposition

Jul 17, 2019

Notification Of Possible Opposition Sent To Ib

Jul 17, 2019

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jul 3, 2019

Notification Of Notice Of Publication E-Mailed

Jun 19, 2019

Assigned To Lie

Jun 7, 2019

Approved For Pub - Principal Register

May 30, 2019

Teas/Email Correspondence Entered

May 29, 2019

Correspondence Received In Law Office

May 29, 2019

Teas Request For Reconsideration Received

Apr 13, 2019

Notification Of Final Refusal Emailed

Apr 13, 2019

Final Refusal E-Mailed

Apr 13, 2019

Final Refusal Written

Mar 22, 2019

Teas/Email Correspondence Entered

Mar 21, 2019

Correspondence Received In Law Office

Mar 21, 2019

Teas Response To Office Action Received

Oct 13, 2018

Refusal Processed By Ib

Sep 21, 2018

Non-Final Action Mailed - Refusal Sent To Ib

Sep 21, 2018

Refusal Processed By Mpu

Sep 18, 2018

Non-Final Action (Ib Refusal) Prepared For Review

Sep 17, 2018

Non-Final Action Written

Sep 12, 2018

Assigned To Examiner

Aug 28, 2018

Application Filing Receipt Mailed

Aug 24, 2018

New Application Office Supplied Data Entered In Tram

Aug 23, 2018

Sn Assigned For Sect 66a Appl From Ib